COVID-19 is no longer an approaching threat to clinical trials, now the concern for biotechs is how to manage their trials through the crisis. According to a recent survey, on-the-fly protocol amendments are fast becoming a necessity, and companies want assurance regulators will be flexible with the resulting datasets. Over three quarters of the 99 survey respondents said their ability to start new trials or to continue active trials has been hindered by the coronavirus.
